SecBot SecBot

PCVX

Vaxcyte, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001649094 Biotech & Drug Discovery
$61.61 −1.76 (−2.78%)
Nov 16 4:00 PM ET · prev $63.37
Market cap
$10.2B
Large cap
Consensus
Buy
88% Buy or better · 17 analysts
Median target
$121.00
+96% · range $75.00–163.00
1 year
+27.5%
from $48.34 · Nov 17
30 days
−3.3%
from $63.68
52-week range
$43.06–73.82
−17% from high · low Dec 17
Avg volume 20D
1.80M
shares / day
Short interest
15.36M
≈9.7% of shares · +5.0%
Days to cover
6.7
at average volume
Insider net
−$6.8M
0 buyers · 4 sellers · since Jul 27
New fund stakes
0
Q2 2026 13F · 5 exits
Filing reports
25
analyzed by SecBot
SecBot read MIXED 16 reports · 90 days
Balance 4 bearish · 2 bullish · 1 mixed · 9 neutral oldest → newest, height = score
Avg score ·High conf. 12/16

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $6.8M.

  • InstitutionsMIXED

    Q2 2026: 32 added (0 new), 29 trimmed or exited.

  • AnalystsBULLISH

    15 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$2.050 → −$1.907 over 90 days. 4 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +5.0% to 15.36M shares. 6.7 days to cover, ≈9.7% of shares.

  • TrendDOWNTREND

    1% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
5
exits
FundMoveSharesValue
FMR LLCADD20,852,907$1.2B
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED2,988,999$173.8M
WESTFIELD CAPITAL MANAGEMENT CO LPTRIM2,472,428$143.7M
D. E. Shaw & Co., Inc.TRIM1,901,872$110.6M
DIMENSIONAL FUND ADVISORS LPDOUBLED1,194,754$69.4M
ADAGE CAPITAL PARTNERS GP, L.L.C.DOUBLED880,000$51.2M
AMERICAN CENTURY COMPANIES INCDOUBLED782,184$45.5M
UBS Group AGTRIM776,511$45.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 88% rate it Buy or better
Strong Buy7Buy8Hold2Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +96%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Oct 12, 2026Cantor Fitzgerald
REITERATE
REITERATEOverweight
Oct 5, 2026BTIG
REITERATE
REITERATEBuy
Oct 5, 2026Needham
MAINTAIN
MAINTAINBuy
Oct 5, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Sep 28, 2026B of A Securities
MAINTAIN
MAINTAINBuy
Sep 25, 2026Needham
REITERATE
REITERATEBuy

Washington

Corporate Lobbying

15 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$6.8M
sold · 4 insiders
DateInsiderTypeValue
Nov 11, 2026
Dhaliwal Harpreet S.
Chief Technical Ops Officer
Nov 11, 2026
EXERCISE$421.4K
Nov 11, 2026
Dhaliwal Harpreet S.
Chief Technical Ops Officer
Nov 11, 2026
SELL$480.4K
Nov 11, 2026
Dhaliwal Harpreet S.
Chief Technical Ops Officer
Nov 11, 2026
SELL$636.9K
Nov 11, 2026
Dhaliwal Harpreet S.
Chief Technical Ops Officer
Nov 11, 2026
SELL$35.8K
Nov 2, 2026
Cowan Elvia
SVP, Finance & CAO
Nov 2, 2026
SELL$146.7K
Nov 2, 2026
Cowan Elvia
SVP, Finance & CAO
Nov 2, 2026
EXERCISE$77.8K
Nov 2, 2026
Wassil Jim
EVP, Chief Scientific Ofc, COO
Nov 2, 2026
SELL$21.1K
Nov 2, 2026
Cowan Elvia
SVP, Finance & CAO
Nov 2, 2026
SELL$36.1K

Earnings setup

Estimates
−$1.91
EPS estimate, this quarter
+7%
estimate change, 90 days
4↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.91-$2.35–-$1.31+15.2%$0.00
Next Q-$1.51-$2.00–-$0.97-14.1%$0.00
Current FY-$7.86-$8.62–-$7.18+7.9%$0.00
Next FY🔒 Fresh data, subscribers only
Congressional trades
PCVX trades disclosed by members of Congress, with disclosure delay.
1 members · 3 buys / 0 sells
DateMemberType AmountDisclosed
Jul 16, 2026 Gilbert CisnerosDHouse VAXCYTE INC BUY $1K–$15K Sep 4, 2026 +50d
May 13, 2026 Gilbert CisnerosDHouse VAXCYTE INC BUY $1K–$15K Jun 8, 2026 +26d
May 12, 2026 Gilbert CisnerosDHouse VAXCYTE INC BUY $1K–$15K Jun 8, 2026 +27d

Short side

FINRA· Oct 30, 2026
15,359,758
shares short
+5.0%
vs prior settlement
6.7
days to cover
≈9.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 Clinical trial readout
Results Pending: 31-valent pneumococcal conjugate vaccine (Phase 3), completed 19d ago
Trial: Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococca
Nov 12, 2026 SEC
Harpreet S. Dhaliwal, an officer of Vaxcyte, filed a Form 144 notice of intent to sell 17,000 common shares with an…
144 · Impact 2/10
Nov 11, 2026 Insider
Dhaliwal Harpreet S. acquired via exercise 17,000 shares
Chief Technical Ops Officer @ $24.79 ($421.4K)
Nov 11, 2026 Insider
Dhaliwal Harpreet S. sold 7,135 shares
Chief Technical Ops Officer @ $67.33 ($480.4K)
Nov 11, 2026 Insider
Dhaliwal Harpreet S. sold 9,345 shares
Chief Technical Ops Officer @ $68.16 ($636.9K)
Nov 6, 2026 SEC
T. Rowe Price Investment Management filed an amended Schedule 13G disclosing an 11.6% passive stake in Vaxcyte as of…
SC 13G/A · Impact 3/10
Oct 5, 2026 Press
Vaxcyte announced positive topline results from the OPUS-1 pivotal Phase 3 trial of VAX-31, its 31-valent pneumococcal…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

25 filings · 4 press releases · 1 bullish · 5 bearish · 19 neutral
All PCVX filing & press-release reports (29)